PD-L1 IHC 22C3 pharmDx
Agilent Technologies, Inc. · Decision date Sep 11, 2026
What did the FDA decide?
The FDA recorded a 30-Day Notice decision, OK30, dated 2026-09-11 for supplement P150013/S035 to Agilent Technologies, Inc.'s PD-L1 IHC 22C3 pharmDx, an immunohistochemistry antibody assay for programmed death-ligand 1 under product code PLS in the pathology specialty. The recorded statement covers approval of manufacturing process and equipment changes for filling and capping.
This action concerns the manufacturing process rather than a new approval of the assay itself; the supplement reason is listed as a process change involving manufacturer, sterilizer, packager or supplier. The source record does not identify which filling or capping equipment changed, the sites involved, or any supporting validation data, and no linked FDA documents are included. Whether the change affects assay performance or labeling cannot be determined from this record.
The decision date is in the future relative to typical publication timelines, and the record provides no clinical, analytical or legal detail beyond the fields shown. Readers should treat the scope as limited to the stated manufacturing change.
FDA approval order statement
approval of manufacturing process and equipment changes for filling and capping
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Pathology
- Decision date
- Sep 11, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P150013/S035
- Regulatory pathway
- PMA supplement
- Applicant
- Agilent Technologies, Inc.
- Product code
- PLS
- Decision code
- OK30
- Decision date
- Sep 11, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Immunohistochemistry assay, antibody, programmed death-ligand 1.
- Applicant
- Agilent Technologies, Inc.
- Product code
- PLS
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P150013. Subsequent supplements may change the device or its indications.
FDA decision timeline
P150013 · Original PMA
PD-L1 IHC 22C3 PHARMDX
P150013/S035 received
Application receipt date recorded by FDA.
P150013/S035 · FDA decision
30-Day Notice
P150013/S034 · Related supplement
PD-L1 IHC 22C3 pharmDx
Timeline entries are records held by MedtechLedger for P150013. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P150013
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
PD-L1 IHC 22C3 PHARMDXP150013 | Agilent Technologies, Inc. | PMA approval | Oct 2, 2015 | FDA |
PD-L1 IHC 22C3 pharmDxP150013/S034 | Agilent Technologies, Inc. | PMA supplement | Sep 21, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Agilent Technologies, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 5301 Stevens Creek Blvd., Santa Clara, CA, 95051
Sources and methodology
- Original FDA record: P150013/S035
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
